Related Experiment Video
Updated: Jun 12, 2025
05:29
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
2.8K
Capivasertib
Emily M Hitt1, Danial E Baker2
1Pharmacotherapy Department, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.
Hospital Pharmacy
|September 25, 2024
Summary
The Formulary Monograph Service provides monthly drug monographs for Pharmacy and Therapeutics Committees, aiding in medication use evaluations and informed prescribing decisions for healthcare facilities.
Area of Science:
- Pharmaceutical Sciences
- Health Services Research
Background:
- Pharmacy and Therapeutics Committees require timely, evidence-based drug information.
- New drug approvals and late-stage trial data necessitate ongoing evaluation of medication use.
Purpose of the Study:
- To provide a detailed overview of The Formulary Monograph Service.
- To highlight the service's utility for healthcare professionals and institutions.
Main Methods:
- Monthly delivery of 5-6 detailed monographs on new or late-phase trial drugs.
- Inclusion of 1-page summary monographs for pharmacy and nursing in-services.
- Provision of comprehensive drug utilization evaluation/medication use evaluation (DUE/MUE) reports.
Main Results:
- Subscribers receive accessible, well-documented drug information.
- Monographs are available online and can be customized for specific facility needs.
- Selected reviews are published in Hospital Pharmacy through collaboration.
Conclusions:
- The Formulary Monograph Service supports informed formulary management and medication use.
- The service offers valuable resources for Pharmacy and Therapeutics Committees and clinical staff.
- Subscription provides continuous access to drug evaluation tools and data.
More Related Videos
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
149
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
149
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
146
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
146
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
791
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
791
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
266
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
266
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
924
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
924